Market Tracker

08/31 5:16pm ET

Merck & Co Inc (NYSE:MRK)

62.79
Delayed Data
As of 4:00pm ET
 +0.08 / +0.13%
Today’s Change
47.97
Today|||52-Week Range
64.00
+18.88%
Year-to-Date
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth
5:14pm / GuruFocus News - Paid Partner Content
Pharmaceuticals are the New Bonds
Aug 26 / GuruFocus News - Paid Partner Content
Will Merck (MRK) Stock Be Helped by Bullish Bernstein Note?
1:53pm / TheStreet.com - Paid Partner Content
Tight Trading on Thursday with Stocks Ending Lower
Aug 25 / GuruFocus News - Paid Partner Content
Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal
12:48pm / TheStreet.com - Paid Partner Content
3 Reasons Gilead Sciences Inc. Stock Could Fall
Aug 25 / MotleyFool.com - Paid Partner Content
Bristol-Myers Squibb misses mark with cancer drug
Aug 30 / FT.com - Paid Partner Content
ETFs in Focus on Pfizer's Medivation Acquisition
Aug 22 / Zacks.com - Paid Partner Content
Intermediate Trade: Merck
Aug 30 / TheStreet.com - Paid Partner Content
2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now
Aug 18 / MotleyFool.com - Paid Partner Content
Cramer: The 'Just You Wait' Crowd Keeps Waiting
Aug 29 / TheStreet.com - Paid Partner Content
Gilead: breaking the fever
Aug 17 / FT.com - Paid Partner Content
Gilead Was Smart to Let Medivation Slip Through its Fingers
Aug 29 / GuruFocus News - Paid Partner Content
Stocks are hot again. But are they too hot?
Aug 16 / CNNMoney.com
The EpiPen Scandal Is Worse Than You Think: What Youre Not Being Told
Aug 27 / Investing Channel - Paid Partner Content
Allergan setback prompts healthcare slide
Aug 08 / FT.com - Paid Partner Content
US Stocks Lower Friday With Hawkish Tone From Fed
Aug 26 / GuruFocus News - Paid Partner Content
Bristol-Myers' value plunges $23bn after cancer drug fails trial
Aug 05 / FT.com - Paid Partner Content